Tomer Kariv - 15 Jun 2022 Form 4 Insider Report for Eloxx Pharmaceuticals, Inc.

Role
Director
Signature
/s/ Sumit Aggarwal, Attorney-in-Fact for Tomer Kariv
Issuer symbol
N/A
Transactions as of
15 Jun 2022
Net transactions value
$0
Form type
4
Filing time
17 Jun 2022, 08:24:38 UTC
Previous filing
03 Jun 2022
Next filing
30 Nov 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ELOX Stock Options (Right to Buy) Award $0 +20,000 $0.000000 20,000 15 Jun 2022 Common Stock 20,000 $0.2600 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option vests as to 50% of the underlying shares on June 15, 2023 and the remainder in twelve (12) equal monthly installments thereafter.
F2 The Reporting Person will assign the economic interests of this grant to the Pontifax funds, where he serves as a director of the General Partner.